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Abstract
Objective—To perform an exploratory
analysis of the relative contribution of sin-
gle MHC genes to the pathogenesis of sys-
temic lupus erythematosus (SLE) in a
homogenous white population.
Methods—MHC class II alleles and C4
allotypes were determined in 64 SLE
patients and in ethnically matched con-
trols. HLA-DR and DQ typing was per-
formed by polymerase chain reaction
amplification with sequence specific
primers. C4 allotypes were determined by
agarose gel electrophoresis.
Results—The frequency of C4A*Q0 was
significantly higher in patients than in
controls (46.9% v 25.3%, p=0.002). HLA-
DRB1, DQA1, and DQB1 alleles in the
whole group of SLE patients were not sig-
nificantly diVerent from those of controls.
On the other hand increase in DRB1*03
was observed in the group of patients with
C4A*Q0, as compared with patients with
other C4A allotypes (p=0.047). There was
no significant correlation between severe
and mild disease, as judged by the
SLEDAI, and HLADR, DQ alleles and
comparing the patients with C4A*Q0 with
those with other C4A allotypes there was
no significant diVerence regarding clinical
manifestations.
Conclusion—The results are consistent
with the argument that C4A deficiency
contributes independently to susceptibil-
ity and the pathogenesis of SLE. C4A*Q0
in SLE patients in Iceland shows weaker
linkage disequilibrium with DR3 genes
than reported in most other white
populations and emphasises the role of
ethnicity.
(Ann Rheum Dis 1998;57:503–505)
A number of studies have shown associations of
certain serological HLA specificities with
systemic lupus erythematosus (SLE); B8,
DR2, and DR3 have shown the strongest
associations.1 The nature of this relation is,
however, obscure as the strength of these asso-
ciations varies from study to study and associa-
tions can vary in ethnically diVerent
populations.2
The two components of complement
component four, C4A and C4B are encoded
by separate two closely linked polymorphic
loci. Thirty five diVerent alleles have been
identified, including non-expressed, or “null”
alleles (“*Q0”), 13 alleles for C4A and 22 for
C4B.3 C4A null has been associated with SLE
in several ethnically diverse populations.1
There are however a few studies that do not
find such an increased frequency of C4A*Q0
in SLE.4 5
The molecular basis for C4A deficiency dif-
fers from one racial group to another and even
within the same ethnic group. A large deletion,
involving most of the C4A gene and part of the
21 OHA gene has been reported to account for
up to two thirds of C4A null in a white popula-
tion with SLE by virtue of HLA-B8, DR3.1
However, recent studies indicate that gene
deletion may not be the basis for C4A*Q0 in
other ethnic groups with diverse HLA types.3
Non-deleted but non-functional C4A alleles
have been described in Asian6 and Mexican
patients as well as in some white and black
populations.7
Therefore the genetic basis for C4A*Q0 in
SLE seems to be heterogenous, and linkage
disequelibrium makes it diYcult to assess the
relative contribution of HLA and C4A*Q0 to
disease susceptibility. The need to pay atten-
tion to ethnicity in both patients and controls
in genetic studies of white populations in SLE
has recently been emphasised.4
Methods
PATIENTS AND CONTROLS
The Icelandic population (260 000) is white,
with ethnic origin most likely from the Nordic
countries and Ireland. The patient group con-
sisted of 57 women and seven men (table 1).
They all fulfilled four or more ARA criteria for
the classification of SLE. Disease severity was
judged by the Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI).8 Included in
this group of 64 patients there are 16 patients
from seven multicase families where the intra-
familial relationship is of the first or second
degree. Patients and controls were from the
Icelandic population.
Table 1 Clinical characteristics of the 64 patients
Total number of patients 64
Women (%) 57 (89.1)
Men (%) 7 (10.9)
Mean age and range at first symptoms 29.4 (9–70)
Mean number of ARA criteria 6.3 (4–10)
Major organ involvement (%) 28 (43.7)
Renal involvement (%) 13 (20.3)
ANA (%) 64 (100)
Anti-dsDNA antibodies (%) 51 (79.6)
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HLA TYPING
HLA-DR and DQ typing was performed on
genomic DNA extracted from peripheral blood
leucocytes by polymerase chain reaction ampli-
fication with sequence specific primers
(PCR-SSP).9
PHENOTYPING OF C4
C4 allotypes were determined by high voltage
agarose electrophoresis on carboxypeptidase
and neuraminidase treated samples followed by
immunofixation.10
An attempt was made to select serum
samples for C4 electrophoresis from periods of
low disease activity.
STATISTICAL METHODS
The ÷2 test with Yates’s correction was used for
statistical analysis. The level of significance was
selected as 0.05. Ninety five per cent confi-
dence intervals are given for diVerences in pro-
portions.
Results
The frequencies of HLA-DRB1, DQA1, and
DQB1 alleles were not significantly diVerent in
the whole group of patients compared with
controls (table 2). On the other hand the
frequency of C4A*Q0 was significantly higher
than in controls (p=0.002). Four patients were
homozygous for C4A*Q0. C4B*Q0 was not
significantly diVerent in patients compared
with controls.
DRB1*03 was higher in the group of
patients with C4A*Q0 compared with those
with other C4A allotypes (p=0.047) (table 3).
As relationship between the 16 patients in
the seven families might bias the results, the
following was done to assess if this had any
eVect: (1) all 16 patients from the seven
families were excluded and alternatively, (2) at
random only one patient from each of the seven
families was included. This did not change the
results: C4A*Q0 was found in 50% and in 49%
of SLE patients respectively compared with
25.3% in controls.
There was no significant correlation between
severe and mild disease, as judged by the high-
est SLEDAI during the disease course, and
HLA DR, DQ alleles. Comparing all of the
patients with C4A*Q0 with those with other
C4A allotypes there was no significant diVer-
ence regarding the mean age of onset or the
severity of disease including renal involvement.
Discussion
The findings in this study are diVerent from
most previous studies in white populations
including studies on SLE patients from
Scandinavia4 11 in which B8, DR2, DR3 have
shown the strongest associations. On the other
hand the increased frequency of C4A*Q0 in
our patient group is consistent with many other
reports in ethnically diverse populations.1 5 11
Only 23.4% of the whole group of the
Icelandic SLE patients, 36.7% of those with
C4A*Q0 and only 15.7% of the controls had
DR3. This is diVerent from other white popu-
lations and suggests diVerent linkage disequi-
librium in the Icelandic population.
This study along with the studies by Schur et
al from USA and by Goldstein et al from
Canada4 emphasise ethnic diVerence regarding
MHC markers in SLE even within white
populations. As a possible explanation for the
diVerence in the frequencies of HLA alleles in
our study and some other studies in Scandina-
vians the question arises if there is a selection
bias regarding the severity of disease. However,
in this study no significant diVerence was
found between mild and severe disease, as
judged by the SLEDAI, regarding HLA-DR,
DQ and C4A alleles, but the power of these
calculations is small because of the small num-
bers in these subgroups.
The findings in this study are consistent with
the hypothesis that C4A deficiency contributes
to susceptibility of SLE. There are several
strong arguments suggesting that in SLE the
disease predisposition may primarily result
from a deficiency of the C4A protein. The find-
ings of increased frequency of C4A*Q0 in
diVerent ethnic groups irrespective of HLA
associations, the molecular heterogeneity of
C4A*Q0 in SLE, and the finding of markedly
increased relative risk when C4A*Q0 occurs in
the homozygous form are consistent with that
theory.12
Additional support for this theory is the
association of SLE with deficiencies of other
complement components; C1q, C1r and C1s
and C3; the structural genes for these compo-
nents show no linkage to the MHC.13
Recent studies of immune complex handling
and success with replacement therapy in a
patient with C2 deficiency and SLE have
further elucidated the importance of intact
function of the classic complement pathway in
the clearance of immune complexes and
supported the theory of a causal relation
between complement deficiency and SLE.14 15
It seems reasonable to speculate that deficiency
of the C4 protein would predispose to immune
complex disease in a similar manner. Whether
the same is true for partial deficiency (hetero-
zygote) has yet to be demonstrated.
This study was done on an ethnically
homogenous and well defined group of patients
and controls. There are not many previous
Table 2 Distribution in the group of 64 Icelandic patients of those DR,DQ, and C4A
alleles most frequently reported to be associated with SLE in a white population
SLE n (%) Control n (%) p Value
DRB1*03 15/64 (23.4) 37/236 (15.7) NS (0.3)
DQA1*0501 16/64 (25.0) 47/170 (27.6) NS
DQB1*0201 13/64 (20.3) 33/180 (18.3) NS
DRB1*15 26/64 (40.6) 95/236 (40.3) NS
DQA1*0102 37/64 (57.8) 91/170 (53.5) NS
DQB1*0602 26/64 (40.6) 70/180 (38.9) NS
C4A*Q0 30/64 (46.9) 49/194 (25.3) 0.002 (DiVerence 22.1%
with 95% CI 8.6, 35.6%)
Table 3 Frequency of DRB1*03,DQA1*0501, and DQB1*0201 in patients with
C4A*Q0 compared with other C4A allotypes
C4A*Q0
n (%)
Other C4A allotypes
n (%) p Value
DRB1*03 11/30 (36.7) 4/34 (11.8) 0.04 (DiVerence 24.9%
with 95% CI 4.1, 45.0%)
DQA1*0501 10/30 (33.3) 6/34 (17.6) NS (0.25)
DQB1*0201 10/30 (33.3) 6/34 (17.6) NS (0.25)
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studies of SLE patients in which careful ethnic
matching of controls has been attempted. We
therefore consider this study an important con-
tribution to genetic studies on SLE.
The results of our study support the theory
that deficiency of complement proteins, in this
instance C4A*Q0, may contribute to the
pathogenesis of SLE. However, many studies
indicate that the inheritance of SLE may be
polygenic and there may be additional uniden-
tified genes that determine susceptibility to
SLE. Our results strongly support the impor-
tance of ethnic background and indicate that
the relative importance of diVerent genes may
vary in diVerent populations.
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